Fortress Biotech
FBIO
55 hedge funds and large institutions have $17.4M invested in Fortress Biotech in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 9 reducing their positions, and 9 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 9
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
2% more funds holding
Funds holding: 54 → 55 (+1)
0.14% more ownership
Funds ownership: 0.65% → 0.78% (+0.14%)
5% less capital invested
Capital invested by funds: $18.4M → $17.4M (-$959K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.15M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$560K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$411K |
| 4 |
Millennium Management
New York
|
+$389K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$308K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$385K |
| 2 |
OGC
One68 Global Capital
New York
|
-$274K |
| 3 |
6CM
683 Capital Management
New York
|
-$172K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$136K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$99K |
FBIO Hedge Fund Activity: Q1 2020 in Review
55 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech (FBIO) for Q1 2020, worth a combined $17.4M — down 5.2% from $18.4M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new FBIO positions and 9 closed out — a net gain of 3 holders — while 18 added to existing stakes and 9 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $3.15M. The largest seller was Oxford Asset Management, cutting an estimated $385K.
- 55 institutional investors held Fortress Biotech (FBIO) as of Q1 2020, up from 54 in Q4 2019.
- Funds reported $17.4M of Fortress Biotech stock for Q1 2020, down 5.2% quarter-over-quarter.
- 12 funds opened new Fortress Biotech positions in Q1 2020 and 9 closed out, a net change of +3 holders.
- The largest Fortress Biotech buyer in Q1 2020 was Nantahala Capital Management, an estimated $3.15M added.
- The largest Fortress Biotech seller in Q1 2020 was Oxford Asset Management, an estimated $385K sold.
Based on aggregated 13F filings for Q1 2020.